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P U B L I S H E D B Y E L S E V I E R I N C .LettersTelomere Maintenance
Is a Critical Determinant
in the Physiopathology of
Pulmonary HypertensionIdiopathic pulmonary arterial hypertension (iPAH) is
a rare disease that occurs sporadically and in which
pulmonary arterial pressure elevation leads to right1 Growth Kinetics and Telomere Length in PA-SMCs From
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’ group are longer than in controls.heart failure and death. Although the fundamental
causes remain elusive, vascular remodeling due to
increased proliferation of pulmonary artery smooth
muscle cells (PA-SMCs) constitutes a key feature (1,2),
thus supporting the comparison between iPAH and
cancer. Given the well-established link between
telomere length and cell proliferation capacity, here
we investigated the telomere status of PA-SMCs and
its relationship to abnormal cell growth.
The local ethics committee (CPP Ile-de-France VII,
Le Kremlin-Bicêtre, France) approved the study. We
studied specimens from patients (informed and with
consent) with iPAH and from control subjects un-
dergoing lung transplantation or lobectomy for
localized lung cancer.
For statistical analysis, all results are reported as
mean  SEM. The Mann-Whitney nonparametric test
was used for comparison between groups.
In situ proliferating PA-SMCs were localized by
immunostaining and counted in lung sections by
using anti-proliferating-cell nuclear antigen. Then,
positive cells/artery were counted, and the results
were expressed as the ratios of positive cells over
total cells.
Human PA-SMCs were isolated and cultured as
previously described (2). Telomere length was esti-
mated both by Southern blotting (terminal restriction
fragments) or by quantitative polymerase chain
reaction (3).
To assay proliferation potential, PA-SMCs were
maintained in culture and were counted at each
passage to determine population doubling levels.
In situ, the percent of proliferating (proliferating-
cell nuclear antigen positive) PA-SMCs was signiﬁ-
cantly higher in patients with iPAH than in control
subjects (data not shown). Ex vivo, as illustrated
by the cumulative population doubling levels
(Figure 1A), PA-SMCs from iPAH patients grew faster
and for a longer time than in control subjects, indi-
cating a higher proliferation capacity in the former.
Interestingly, iPAH PA-SMCs also carried longer
telomeres than control subjects (telomere repeat copy
number to single gene copy number ratio [T/S] mean
0.917 vs. 0.672; Mann-Whitney test, p ¼ 0.00084),
and in contrast to control subjects, telomere length
was maintained with increasing passages (data not
shown).
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1943Longer telomeres in PA-SMCs from iPAH patients
did not correlate with age (Figure 1B). Strikingly,
telomere lengths in iPAH positively and signiﬁcantly
(Spearman rank correlation r2 ¼ 0.818; p ¼ 0.00096)
correlated with pulmonary vascular resistance
values, suggesting a strong relationship between
disease severity and better telomere length mainte-
nance. This phenomenon seems to be exclusive to
PA-SMCs, because it was not found in matched
endothelial cells or peripheral blood cells (data not
shown).
Alterations in the proliferation capacity of the PA-
SMCs have been associated with pulmonary hyper-
tension. Recent studies have also highlighted the
similarities between iPAH and cancer, 2 diseases
that involve abnormal cell growth. Here, we extend
these similarities to aspects related to telomere
biology and show the correlation between telomere
maintenance and proliferation capacity of iPAH PA-
SMCs, as well as disease severity. This correlation,
probably related to an increase of telomerase activity
(4), seems to be exclusive to iPAH, because it was not
found in chronic obstructive pulmonary disease pul-
monary hypertension (5), suggesting that the mech-
anisms involved in the PA-SMC abnormal growth are
different. In conclusion, our work suggests that in
iPAH, PA-SMCs overcome the proliferation barriers
that operate in normal cells through a better main-
tenance of telomeres.Mohamed Izikki, PhD
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Necessary Before
Adenosine-Induced
Fractional Flow
Reserve Measurement?Caffeine antagonizes the pharmacological actions of
adenosine by blocking adenosine receptor activity (1).
A protocol for adenosine stress myocardial perfusion
imaging recommends that caffeine-containing prod-
ucts be withheld for 12 h before the test (2). However,
there has been no widely accepted consensus for the
need of caffeine abstention before fractional ﬂow
reserve (FFR) measurement. Conﬂicting results have
been reported in the literature concerning the effects
of caffeine on FFR measurement (3,4). Thus, we
designed this study to determine if caffeine absten-
tion is required before FFR measurement and if high-
dose intracoronary adenosine overcomes the caffeine
antagonism.
This prospective, single-center study enrolled
76 patients who underwent clinically indicated FFR
assessment. Of these patients, 19 patients in each
group were asked to refrain from caffeine-containing
products for 12, 24, and 48 h before the test and 19
patients were allowed to have caffeine. Exclusion
criteria included acute myocardial infarction, severe
arrhythmia, previous coronary artery bypass grafting,
any contraindications for adenosine or papaverine,
and the presence of pressure drift (>0.03) after pull-
back. Hyperemia was induced by central intravenous
adenosine at a dose of 140 mg/kg/min (ADN-IV), by
intracoronary adenosine at varying doses (60 mg
[ADN-IC60], 150 mg [ADN-IC150], 300 mg [ADN-IC300],
by 600 mg [ADN-IC600]), and by papaverine (10 to
12 mg in the right coronary artery or 15 to 20 mg in the
left coronary artery), as a reference standard. The
